Hansen-Pupp I, et al. - In this present study, the clinicians examined the feasibility of continuous longitudinal intravenous infusion of rhIGF-1/rhIGFBP-3 for prevention of retinopathy of prematurity and other complications in extremely preterm infants (<28 weeks' gestational age). They explained that infusion of rhIGF-1/rhIGFBP-3 increased serum concentrations of IGF-1 and attainment of target levels relative to standard neonatal care. Moreover, rhIGF-1/rhIGFBP-3 infusion was well tolerated with no major adverse events. However, further studies were needed to optimize the dose regimen for the attainment of physiological intrauterine levels.